TSR-011

TSR-011 is an orally available ALK inhibitor being developed for the treatment of solid tumors including NSCLC. ALK is known to be involved in certain types of cancers, including subsets of non-small cell lung cancer, neuroblastoma and lymphoma. TSR-011 is a potent inhibitor of both anaplastic lymphoma kinase (ALK) and tropomyosin-related kinases (TRK). Preliminary results after eight weeks of treatment with TSR-011 demonstrated disease control (partial responses plus stable disease) in 11 of 17 (65%) evaluable patients treated with TSR-011.